Afimoxifene
 |
|
| Names | |
|---|---|
| IUPAC name
(Z)-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
|
|
| Other names
4-hydroxytamoxifen
|
|
| Identifiers | |
68392-35-8  |
|
| ChEMBL | ChEMBL489  |
| ChemSpider | 395987 |
| Jmol 3D model | Interactive image Interactive image |
| KEGG | D06551 |
| PubChem | 449459 |
| UNII | 17197F0KYM |
|
|
|
|
| Properties | |
| C26H29NO2 | |
| Molar mass | 387.51396 |
| Vapor pressure | {{{value}}} |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
 verify (what is ?) |
|
| Infobox references | |
Afimoxifene[1] (4-hydroxytamoxifen) is a selective estrogen receptor modulator which is the active metabolite of tamoxifen.[2] Afimoxifene is a transdermal gel formulation and is being developed by Ascend Therapeutics, Inc. under the trademark TamoGel.[1]
Afimoxifene has completed a phase II clinical trial for the treatment of cyclical mastalgia.[3]
A study in France on 55 women showed that rubbing afimoxifene on the skin was as good as tamoxifen tablets at slowing breast cancer growth. A US trial will compare 6 weeks use before breast cancer surgery. Skin application can reduce systemic levels by a factor of nine and this is expected to reduce the unpleasant side-effects of tamoxifen.[4]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." />External links
- 4-hydroxytamoxifen at the US National Library of Medicine Medical Subject Headings (MeSH)
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
